DE60232101D1 - - Google Patents
Info
- Publication number
- DE60232101D1 DE60232101D1 DE60232101T DE60232101T DE60232101D1 DE 60232101 D1 DE60232101 D1 DE 60232101D1 DE 60232101 T DE60232101 T DE 60232101T DE 60232101 T DE60232101 T DE 60232101T DE 60232101 D1 DE60232101 D1 DE 60232101D1
- Authority
- DE
- Germany
- Prior art keywords
- arthritis
- antibody
- agent
- fgf
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Rehabilitation Therapy (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001400677 | 2001-12-28 | ||
PCT/JP2002/013650 WO2003057251A1 (fr) | 2001-12-28 | 2002-12-26 | Remedes contre l'arthrite |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60232101D1 true DE60232101D1 (de) | 2009-06-04 |
Family
ID=19189657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60232101T Expired - Lifetime DE60232101D1 (de) | 2001-12-28 | 2002-12-26 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7708999B2 (de) |
EP (1) | EP1466623B1 (de) |
JP (1) | JP4246069B2 (de) |
KR (1) | KR100942402B1 (de) |
CN (1) | CN100389826C (de) |
AT (1) | ATE429249T1 (de) |
AU (1) | AU2002361106B2 (de) |
CA (1) | CA2471938A1 (de) |
DE (1) | DE60232101D1 (de) |
ES (1) | ES2323949T3 (de) |
WO (1) | WO2003057251A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
ATE483799T1 (de) * | 2006-06-09 | 2010-10-15 | Hoffmann La Roche | Hemmung der enzymatischen peroxidaseaktivität |
RU2540150C2 (ru) | 2007-06-25 | 2015-02-10 | Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк | Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
US7662858B2 (en) | 2008-05-23 | 2010-02-16 | Aaipharma, Inc. | Method of treating post-surgical acute pain |
GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
JP7444886B2 (ja) * | 2018-12-11 | 2024-03-06 | キュー32・バイオ・インコーポレーテッド | 補体関連疾患のための融合タンパク質構築物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5491220A (en) * | 1993-09-24 | 1996-02-13 | Yeda Research And Development Co., Ltd. | Surface loop structural analogues of fibroblast growth factors |
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
JP3708210B2 (ja) * | 1996-04-03 | 2005-10-19 | 協和醗酵工業株式会社 | 抗線維芽細胞増殖因子−8モノクローナル抗体 |
BRPI9712348C8 (pt) * | 1996-10-16 | 2020-04-22 | Zymogenetics Inc | vetor de expressão, célula de bactéria ou levedura transformada ou transfectada, processo para produzir um polipeptídeo homólogo de fgf, composição farmacêutica, e, processos para estimular ex vivo células progenitoras de miócitos ou miócitos |
JP4550947B2 (ja) * | 1997-03-19 | 2010-09-22 | 協和発酵キリン株式会社 | ガングリオシドgm2に対するヒト型相補性決定領域(cdr)移植抗体 |
WO2000062809A1 (fr) * | 1999-04-19 | 2000-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de proliferation cellulaire pour tumeurs androgeno-independantes |
JP2001046066A (ja) * | 1999-08-03 | 2001-02-20 | Kyowa Hakko Kogyo Co Ltd | 新規な相補性決定領域を有するヒトvegf受容体kdrに対する抗体 |
ATE393170T1 (de) | 2001-06-28 | 2008-05-15 | Kyowa Hakko Kogyo Kk | Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers |
-
2002
- 2002-12-26 CN CNB028262905A patent/CN100389826C/zh not_active Expired - Fee Related
- 2002-12-26 US US10/500,207 patent/US7708999B2/en not_active Expired - Fee Related
- 2002-12-26 KR KR1020047009998A patent/KR100942402B1/ko not_active IP Right Cessation
- 2002-12-26 AU AU2002361106A patent/AU2002361106B2/en not_active Ceased
- 2002-12-26 AT AT02792021T patent/ATE429249T1/de not_active IP Right Cessation
- 2002-12-26 DE DE60232101T patent/DE60232101D1/de not_active Expired - Lifetime
- 2002-12-26 ES ES02792021T patent/ES2323949T3/es not_active Expired - Lifetime
- 2002-12-26 WO PCT/JP2002/013650 patent/WO2003057251A1/ja active IP Right Grant
- 2002-12-26 CA CA002471938A patent/CA2471938A1/en not_active Abandoned
- 2002-12-26 JP JP2003557608A patent/JP4246069B2/ja not_active Expired - Fee Related
- 2002-12-26 EP EP02792021A patent/EP1466623B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2323949T3 (es) | 2009-07-28 |
JP4246069B2 (ja) | 2009-04-02 |
JPWO2003057251A1 (ja) | 2005-05-12 |
CN1607961A (zh) | 2005-04-20 |
KR100942402B1 (ko) | 2010-02-17 |
AU2002361106B2 (en) | 2007-06-07 |
AU2002361106A1 (en) | 2003-07-24 |
WO2003057251A1 (fr) | 2003-07-17 |
KR20040078652A (ko) | 2004-09-10 |
US7708999B2 (en) | 2010-05-04 |
EP1466623A4 (de) | 2006-05-17 |
ATE429249T1 (de) | 2009-05-15 |
US20050175608A1 (en) | 2005-08-11 |
EP1466623B1 (de) | 2009-04-22 |
EP1466623A1 (de) | 2004-10-13 |
CN100389826C (zh) | 2008-05-28 |
CA2471938A1 (en) | 2003-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002010348A3 (en) | Tissue implant for cartilage repair | |
PL1663185T3 (pl) | Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego | |
MXPA02011427A (es) | Procedimiento para revestir dispositivos medicos utilizando dioxido de carbono supercritico. | |
WO2003039330A3 (en) | Devices and methods to correct spinal deformities | |
WO2000064930A3 (en) | Tribonectins | |
CA2340030A1 (en) | Scaffold fixation device for use in articular cartilage repair | |
DE69728585D1 (de) | Mittel gegen Juckreiz | |
PL346660A1 (en) | Method for treating atherosclerosis employing an ap2 inhibitor and combination | |
WO2004032988A3 (en) | Coupling agents for orthopedic biomaterials | |
AU2002365166A1 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis | |
WO2002064125A3 (en) | Use of a farnesoid x receptor antagonist for treating hyperlipidemia | |
WO2003057100A3 (en) | Device and procedure for refractive laser surgery | |
DE60232101D1 (de) | ||
AU2002323873A1 (en) | Active ingredient combination of E.G. galanthamine or deoxypeganine and E.G. acamprosate or memantine for treating an addiction such as alcoholism | |
MXPA02012907A (es) | Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad. | |
WO2004034961A3 (en) | Antimicrobial agents and uses thereof | |
ITBO980003A0 (it) | Procedimento e relativi impianti per il trattamento e lo smaltimento di rifiuti. | |
WO2003059332A3 (en) | Use of an anti-microtubule agent for the treatment of uveitis | |
EP1469844A4 (de) | Verfahren und verbindung für die prophylaxe oder behandlung eines immunschwächezustands, wie z.b. aids | |
EP1197495A3 (de) | DNA Bindungsprotein YB-1 enthaltende Inhibitoren der Kollagen Ansammlung | |
BR0112460A (pt) | Método para tratamento de sépsis | |
YU24002A (sh) | Sredstvo sa višestrukim probama i postupak za brzu i visoko specifičnu detekciju pseudomonas aeruginosa | |
AU2002352228A1 (en) | Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment | |
AU2003287513A1 (en) | INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT | |
WO2002078523A3 (en) | Agent for the treatment of overactive bladder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP |
|
8364 | No opposition during term of opposition |